Neuraxis (NRXS) Operating Expenses (2022 - 2025)
Neuraxis (NRXS) posted Operating Expenses of $2.0 million for Q4 2025, up 3.91% sequentially from $1.9 million in Q3 2025, and up 17.46% YoY from $1.7 million in Q4 2024.
Neuraxis (NRXS) Operating Expenses (2022 - 2025) Analysis & Trends
Neuraxis has reported Operating Expenses for 4 years, with the latest figure at $2.0 million in Q4 2025.
- Quarterly Operating Expenses rose 17.46% year-over-year to $2.0 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $6.2 million (down 30.82% YoY) and the FY2025 annual result came in at $8.6 million, up 6.8% from the prior year.
- Operating Expenses advanced to $2.0 million in Q4 2025 per NRXS's latest filing, from $1.9 million in the prior quarter.
- Over five years, Operating Expenses peaked at $3.4 million in Q3 2023 and troughed at $37231.0 in Q4 2023.
- A 4-year average of $1.9 million and a median of $1.8 million in 2024 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2023 and 2024: Operating Expenses plunged 97.45% in 2023, then jumped 4376.75% in 2024.
- Over 4 years, Operating Expenses stood at $1.5 million in 2022, then slumped by 97.45% to $37231.0 in 2023, then surged by 4376.75% to $1.7 million in 2024, then grew by 17.46% to $2.0 million in 2025.
- According to Business Quant data, Operating Expenses over the past three periods registered $2.0 million, $1.9 million, and $2.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 541.02 Mn |
| 10 | Neuraxis | 74.54 Mn | 66.21 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.96 Mn |
| Sep 30, 2025 | 1.88 Mn |
| Jun 30, 2025 | 2.32 Mn |
| Mar 31, 2025 | 2.86 Mn |
| Dec 31, 2024 | 1.67 Mn |
| Sep 30, 2024 | 1.76 Mn |
| Jun 30, 2024 | 2.63 Mn |
| Mar 31, 2024 | 2.32 Mn |
| Dec 31, 2023 | 37,231.00 |
| Sep 30, 2023 | 3.37 Mn |
| Jun 30, 2023 | 1.62 Mn |
| Mar 31, 2023 | 1.50 Mn |
| Dec 31, 2022 | 1.46 Mn |
| Sep 30, 2022 | 1.67 Mn |
| Jun 30, 2022 | 1.15 Mn |